Group 1 - The company Bonduelle is a French S.C.A with a share capital of €57,102,699.50 and is registered under number 447 250 044 in the Dunkerque Commercial and Companies Register [2] - As of December 31, 2024, the total number of shares forming the capital is 32,630,114, with a theoretical total of voting rights amounting to 52,526,634 [2][3] - The actual total number of voting rights, which excludes shares without voting rights, is 51,972,538 [2]

Core Viewpoint - Bon Natural Life Limited has entered a strategic cooperation agreement with Guangdong JUWO Trading Co., Ltd. to develop marketing and supply chain systems for liquor distribution and sales in mainland China, focusing on health-oriented alcoholic products [1][2]. Company Overview - Bon Natural Life Limited is a leading provider of bio-ingredient solutions in the natural, health, and personal care industries [1]. - The company operates through its subsidiary, Xi'an App-Chem Bio (Tech) Co., Ltd., which will collaborate with JUWO on this initiative [1]. Strategic Cooperation Details - The agreement allows JUWO to use the "App-chem" brand for co-branded alcoholic health products, specifically under the name "Jiangwang and App-Chem Co-Branding" [2]. - JUWO will handle the promotion and marketing of these products, leveraging its expertise in Moutai-flavor liquor and extensive distribution channels across China [2][3]. Market and Product Focus - The cooperation aims to create high-quality health alcoholic products that blend traditional Chinese culture with modern technology, utilizing App-Chem's brand influence and JUWO's distribution advantages [3]. - The partnership is expected to enhance the competitiveness of Bon Natural Life in the bio-tech industry and expand its business categories [4]. Leadership Statement - The Chairman and CEO of Bon Natural Life expressed optimism about the partnership, highlighting its potential for growth and the aim to deliver innovative product experiences to consumers [4].

IPO and Financing - The company closed its initial public offering (IPO) on June 28, 2021, raising gross proceeds of $12.65 million from the sale of 2,200,000 ordinary shares at $5.00 per share[203]. - As of the date of the annual report, net proceeds of approximately $9 million from the IPO and $1 million from the over-allotment option were transferred to PRC subsidiaries as intercompany loans[209]. - On March 30, 2023, the company initiated a public offering of up to $3 million worth of ordinary shares, but the offering was terminated on August 3, 2023, due to lack of valid subscriptions[220][222]. - A private offering closed on January 17, 2023, resulting in the issuance of 2,750,000 ordinary shares at a subscription price of $0.80 per share, generating total proceeds of $2.2 million[224]. Compliance and Regulatory Issues - The company received a notification from Nasdaq on June 12, 2023, regarding non-compliance with the minimum bid price requirement of $1.00 per share for thirty consecutive days[218]. - Nasdaq granted the company an additional 180-day period until June 10, 2024, to regain compliance with the bid price requirement[219]. - The company’s ability to distribute dividends is subject to PRC regulations, which may impose restrictions on the remittance of foreign currency for dividend payments[212]. - The company must comply with extensive regulations governing the food industry, including obtaining necessary permits and licenses for production and distribution[314]. Corporate Structure and Operations - The company operates through a direct holding structure, with Bon Natural Life Limited controlling its PRC subsidiaries through its Hong Kong subsidiary, Tea Essence[207]. - The company restructured its corporate structure by terminating VIE agreements, converting Xi'an App-Chem into a Sino-foreign joint venture, and transferring 100% ownership to its subsidiaries, effective November 1, 2021[229][230]. - The company formed a new wholly foreign-owned enterprise, Xi'an Youpincui, on September 8, 2021, and incorporated Bon Natural Life U.S.A. on February 7, 2023[227]. Financial Performance - Key financial performance indicators include growth in net revenue and gross profit, with a focus on controlling costs and improving operating efficiency[232]. - For the year ended September 30, 2023, net revenue was driven by fragrance compounds (48.5%), health supplemental powder drinks (29.5%), and bioactive food ingredients (22.0%)[378]. - Total revenue decreased by 1.3% to $29,522,353 for the year ended September 30, 2023 compared to $29,908,561 in 2022[391]. - Net income decreased by 27.1% to $4,552,682 for the year ended September 30, 2023 compared to $6,242,424 in 2022[389]. Product Development and Innovation - New product developments include Bon Natural Micro-eco Hair Repair Shampoo and Tianmei Jinghao Nutrition Powder, with ongoing innovation in natural functional ingredients[241]. - The company produces ambroxide with a purity of 99.5%, exceeding the industry average of approximately 99.0%, and a yield of approximately 63% compared to the industry average of 40% to 43%[240]. - The company offers customized product development and technical support services to enhance customer loyalty and competitiveness in the marketplace[239]. Market and Competition - The company has established a strong reputation in the natural ingredients industry, particularly in the field of micro-biome health[259]. - Competitor Quantum Hi-Tech has a total market value of approximately $1 billion as of March 2020, indicating a competitive landscape[260]. - BY-HEALTH's total market value reached ¥27.2 billion as of March 2020[267]. Supply Chain and Customer Base - For the year ended September 30, 2023, three suppliers accounted for approximately 41.8%, 29.5%, and 11.19% of total purchases, indicating a significant reliance on key suppliers[255]. - For the year ended September 30, 2023, three customers accounted for 42.7%, 24.7%, and 13.2% of total revenue, highlighting a concentrated customer base[256]. - The total number of customers decreased by 11.3% from 142 in 2022 to 126 in 2023[379]. Production and Operational Challenges - The ongoing COVID-19 pandemic has affected the company's operations, with potential future impacts on revenue and cash flows still uncertain[231]. - The production challenges due to frost damage and pandemic control measures significantly impacted the procurement of key raw materials[397]. - The company shifted to producing low-concentration apple polyphenol juice due to technical challenges in extracting from larger apples[397]. Regulatory Compliance and Certifications - The company has obtained the required Food Production Licenses and Food Business Licenses, including a Food Production License expiring on August 8, 2028, and a Food Business License obtained on November 28, 2022[315]. - Xi'an App-Chem has received REACH certification for ambroxide in the European Union and GRAS certification from the FDA for clary sage[315]. - The company has kosher and halal certifications for certain products, ensuring compliance with various market regulations[315].

Financial Performance - Total revenues for the six months ended March 31, 2023, were $14,149,967, an increase of $461,567, or 3.4%, compared to $13,688,400 in the same period of 2022[5] - Income from operations for the same period was $2,985,234, an increase of $196,875, or 7.1%, compared to $2,788,359 in the same period of 2022[5] - Net income attributable to Bon Natural Life Limited for the six months ended March 31, 2023, was $2,119,760, a decrease from $2,548,678 in the same period of 2022[5] - Basic and diluted earnings per share were both $0.24 for the six months ended March 31, 2023, down from $0.31 and $0.30, respectively, in the same period of 2022[5] Revenue Breakdown - Revenue from health supplement (powder drinks) products increased by 37.2% to $4,583,272, driven by a 50% increase in sales volume from 130,000 cases to 195,035 cases sold[16] - Revenue from fragrance compounds decreased by 8.4% to $6,810,374, primarily due to a 10.1% decrease in average selling price and a 9.5% negative impact from foreign currency fluctuations[14] - Revenues from sales of bioactive food ingredient products decreased by 5.2% to $2,756,320 in the six months ended March 31, 2023, from $2,908,919 in the same period of 2022[18] Cost and Expenses - Total operating expenses increased by 38.8% to $1,732,114, with general and administrative expenses rising by 46.8% to $1,465,955[8] - Selling expenses increased by 62.2% to $136,164 in the six months ended March 31, 2023, from $83,970 in the same period of 2022, primarily due to a significant increase in staff payroll and shipping expenses[29] - General and administrative expenses rose by 46.8% to $1,465,955 in the six months ended March 31, 2023, from $998,943 in the same period of 2022, driven by increases in staff payroll and rent expenses[30] Profitability - Gross profit for the six months ended March 31, 2023, was $4,717,348, representing a gross margin of 33.3%, up from 29.5% in the same period of 2022[8] - Gross profit increased by 16.9% to $4,717,348 in the six months ended March 31, 2023, from $4,035,947 in the same period of 2022, with a gross margin increase from 29.5% to 33.3%[25] - Gross profit from fragrance compound products increased by 12.3% to $2,024,680, while gross profit from health supplement products rose by 21% to $1,414,558 in the same period[25][27] Cash Flow and Financing - Net cash used in operating activities during the six months ended March 31, 2023, was $2,177,992, compared to $130,577 in the same period of 2022[41] - Net cash provided by financing activities during the six months ended March 31, 2023, was $1,914,916, primarily from proceeds of $2,200,000 from the issuance of Ordinary Shares[43] - Cash on hand as of March 31, 2023, was $542,272, a decrease from $1,609,079 at the end of the same period in 2022[41] Other Financial Metrics - Research and development expenses decreased by $34,680, or approximately 21.1%, from $164,675 in the six months ended March 31, 2022, to $129,995 in the same period of 2023[31] - Interest expense, net, decreased by $99,207 or approximately 35.7% in the six months ended March 31, 2023, compared to 2022[33] - Government subsidies received totaled $11,916 in the six months ended March 31, 2023, a significant decrease of 97.8% from $542,256 in the same period of 2022[34] - The provision for income taxes was $510,007 in the six months ended March 31, 2023, a decrease of $52,660 or 9.4% from $562,737 in the same period of 2022[36] - The overall net decrease in cash was $298,589 for the six months ended March 31, 2023, compared to a decrease of $294,788 in the same period of 2022[41] Customer Metrics - The company sold products to 94 customers in the six months ended March 31, 2023, an increase of 8.0% from 87 customers in the same period of 2022[10] - The average purchase order size decreased by 4.5% from approximately $157,000 to $150,000 per customer[10] Product Pricing and Sales Volume - The average price of bioactive food ingredient products decreased by 7.5% from $52.8 to $48.83, while sales volume increased by 2.4% from 55,104 kilograms to 56,444 kilograms due to strong customer demand[18] - The sales volume of health supplement products increased by 50% from 130,000 cases to 195,035 cases in the six months ended March 31, 2023[23] - The cost of revenues for bioactive food ingredient products decreased by 19.8% to $1,478,210, attributed to a 21.7% decrease in weighted average unit cost[24] - The company experienced a 9.5% negative impact from foreign currency fluctuations due to changes in the average exchange rate from RMB to USD[18][20][25] Capital Expenditure - Capital expenditure on construction-in-progress amounted to $15,131 in the six months ended March 31, 2023, compared to $3,577,995 in the same period of 2022[42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-40517 BON NATURAL LIFE LIMITED (Translation of registrant's name into English) 25F, Rongcheng Yungu, Keji 3 Road Xi'an Hi-Tech Zone, Xi'an, China People's Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or wi ...

Bon Natural Life Limited. (NASDAQ:BON) Q4 2022 Earnings Conference Call February 10, 2023 9:00 AM ET Company Participants Unidentified Company Representative - Investor Relations Richard Hu - Chairman and Chief Executive Officer Zhenchao Li - Chief Financial Officer Yingchun Xue - COO Wenjuan Chen - CMO Conference Call Participants Operator Good day and welcome to the Bon Natural Life Fiscal Year 2022 Limited Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. Pl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ OR ☐ SHELL COMPANY REPORT PURSUAN ...

Summary of Bon Natural Life Limited H2 2022 Earnings Conference Call Company Overview - **Company Name**: Bon Natural Life Limited (NASDAQ: BON) - **Industry**: Natural health and personal care, focusing on bioingredient solutions - **Product Categories**: - Fragrance compounds - Health supplements - Bioactive food ingredients - **Key Clients**: Includes major names in Asia and the US/Europe such as International Flavors & Fragrances, Mars Wrigley, and Angel Yeast [3][4] Core Financial Performance - **Revenue**: Approximately $13.7 million for H1 2022, a 17% increase year-over-year [10] - **Gross Profit**: Approximately $4 million, up 19.6% [11] - **Net Income**: Increased from $2.3 million to $2.5 million, a 10.2% rise [12] - **Diluted Earnings Per Share**: $0.30 compared to $0.40 in the same period of 2021 [12] Product Category Performance - **Fragrance Compounds**: Revenue increased by 24.9% from $6 million to $7.4 million, driven by higher average selling prices [12][13] - **Health Supplements**: Revenue decreased by 28.5% from $4.7 million to $3.3 million due to raw material shortages and logistics disruptions [13][14] - **Bioactive Food Ingredients**: Revenue surged by 171.8% from $1.1 million to $2.9 million, attributed to volume growth and higher selling prices [14] Manufacturing and Capacity Expansion - **Yumen Plant**: Construction completed, expected to commence production in September 2022. The plant aims to increase production capacity for fragrance compounds and bioactive food ingredients by 200%, with a projected 150% annualized revenue growth potential [5][24] - **New Product Development**: Introduction of innovative products such as FeatherPure and a broccoli-based probiotic drink, expected to generate approximately $3 million in revenue over two years [6][7] Market Strategy and Growth Outlook - **Domestic vs. International Sales**: Domestic sales accounted for approximately 95.7% of total revenue, with a 22.4% increase. International sales were limited to about $600,000 due to COVID-19 logistics disruptions [15] - **Future Growth Strategies**: Plans to expand product lines, develop new products targeting various health aspects, and pursue mergers and acquisitions to enhance capabilities [8][9] Key Challenges and Considerations - **Supply Chain Issues**: Ongoing challenges due to global supply chain disruptions and inflation affecting raw material costs [21] - **Market Conditions**: The company remains optimistic about maintaining growth despite slower rates compared to previous years due to external factors [22] Additional Insights - **Government Support**: Received approximately $542,000 in government subsidies, indicating continued support for high-tech companies [12] - **Management Confidence**: Leadership expressed confidence in R&D capabilities and business strategies to capture market share and sustain growth momentum [17] This summary encapsulates the key points from the earnings conference call, highlighting the company's performance, strategic initiatives, and market outlook.